Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent clinical trials have exhibited that curcumin, a natural polyphenolic compound, is effective as adjuvant therapy in patients with ulcerative colitis (UC). In this randomized, placebo-controlled, double-blind study, 43 patients with mild-moderate UC who were referred to the gastrointestinal ward of Imam Khomeini Hospital in Tehran, Iran were assessed. They were randomly specified to the intervention (n = 21, SinaCurcumin® soft gel 80 mg) or the placebo (n = 22) group, administered twice a day for 1 month, in addition to 5-aminosalicylic acid. The main consequence of the study was to get to a decrement of at least three scores in the Simple Clinical Colitis Activity Index (SCCAI) within a month. Endoscopic and histopathological responses and Hospital Anxiety and Depression Scale (HADS) score changes were also recorded. The clinical (p = 0.031, χ
Indexed as
Identifiers
40820062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.